BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Milassin Á, Fábián A, Molnár T. Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective. Therap Adv Gastroenterol 2019;12:1756284819842748. [PMID: 31019554 DOI: 10.1177/1756284819842748] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Valor-Méndez L, Dorn C, Manger B, Schett G, Kleyer A. Re-exposure with a TNF inhibitor bio-similar was well tolerated and led to sustained control of psoriatic arthritis after allergic reaction to the TNF inhibitor bio-originator. Rheumatol Adv Pract 2022;6:rkac079. [PMID: 36268524 DOI: 10.1093/rap/rkac079] [Reference Citation Analysis]
2 Pierik MJ, van der Meulen AE, Van der Linde K, Lutgens M, Kuijvenhoven JP, Akol H, Klompmaker IJ, Sikkens MSG, van Megen YJB, Stoop CM, Bloemsaat-minekus JPJ, Dijkstra G. Switching From Reference Infliximab to Biosimilar CT-P13 Did Not Change Quality of Life in Stable Inflammatory Bowel Disease Patients. Crohn's & Colitis 360 2022;4. [DOI: 10.1093/crocol/otab001] [Reference Citation Analysis]
3 Feijó Azevedo V, Moots R. Introductory Chapter: Biosimilars - A Regulatory and Clinical Perspective. Biosimilars 2022. [DOI: 10.5772/intechopen.104746] [Reference Citation Analysis]
4 Peda ES, Alexandrov TL, Baranova TA, Belous SS, Tishaeva IA, Nanaeva BA, Shapina MV, Knyazev OV, Eligulashvili RR, Belinskaya VA, Podolskaya DV. The effectiveness and safety of switching therapy with an original drug to biosimilars in treatment of inflammatory bowel diseases. jour 2022. [DOI: 10.31146/1682-8658-ecg-195-11-35-41] [Reference Citation Analysis]
5 Luber RP, O'Neill R, Singh S, Sharma E, Cunningham G, Honap S, Meade S, Ray S, Anderson SH, Mawdsley J, Sanderson JD, Samaan MA, Arkir Z, Irving PM. An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch. Aliment Pharmacol Ther 2021;54:678-88. [PMID: 34223654 DOI: 10.1111/apt.16497] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Chen L, Xu CJ, Wu W, Ding BJ, Liu ZJ. Anti-TNF and immunosuppressive combination therapy is preferential to inducing clinical remission in patients with active inflammatory bowel disease: A systemic review and meta-analysis. J Dig Dis 2021;22:408-18. [PMID: 34048629 DOI: 10.1111/1751-2980.13026] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Rathore AS, Stevenson JG, Chhabra H, Maharana C. The global landscape on interchangeability of biosimilars. Expert Opin Biol Ther 2021;:1-16. [PMID: 33567923 DOI: 10.1080/14712598.2021.1889511] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Khan N, Patel D, Pernes T, Patel M, Trivedi C, Medvedeva E, Xie D, Yang Y. The Efficacy and Safety of Switching From Originator Infliximab to Single or Double Switch Biosimilar Among a Nationwide Cohort of Inflammatory Bowel Disease Patients. Crohn's & Colitis 360 2021;3:otab022. [DOI: 10.1093/crocol/otab022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Cohen HP, McCabe D. The Importance of Countering Biosimilar Disparagement and Misinformation. BioDrugs 2020;34:407-14. [PMID: 32691270 DOI: 10.1007/s40259-020-00433-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 11.0] [Reference Citation Analysis]
10 Lovero R, Losurdo G, La Fortezza RF, Terracciano F, Biscaglia G, Martino G, Nardella M, Di Leo A, Principi M, Andriulli A, Bossa F. Safety and efficacy of switching from infliximab biosimilar CT-P13 to infliximab biosimilar SB2 in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2021;32:201-7. [PMID: 33369956 DOI: 10.1097/MEG.0000000000001988] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
11 Allocati E, Godman B. Key patient related factors in the management of inflammatory bowel disease. J Med Econ 2020;23:1606-9. [PMID: 33210979 DOI: 10.1080/13696998.2020.1838913] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Talathi S, Baig KRKK. Biosimilars in inflammatory bowel disease. J Dig Dis 2020;21:610-20. [PMID: 32920972 DOI: 10.1111/1751-2980.12940] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
13 Ismailov RM, Pouillon L, Selinger CP, Khasanova ZD. Knowledge and awareness of biosimilars and shared decision-making among gastroenterology team members in Colorado, USA. Expert Opin Biol Ther 2021;21:111-9. [PMID: 33107355 DOI: 10.1080/14712598.2020.1842355] [Reference Citation Analysis]
14 Martín-Gutiérrez N, Sánchez-Hernández JG, Rebollo N, Pordomingo AF, Muñoz F, Otero MJ. Long-term effectiveness and pharmacokinetics of the infliximab biosimilar CT-P13 after switching from the originator during the treatment of inflammatory bowel disease. Eur J Hosp Pharm 2020:ejhpharm-2020-002410. [PMID: 33115797 DOI: 10.1136/ejhpharm-2020-002410] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
15 Kim H, Alten R, Avedano L, Dignass A, Gomollón F, Greveson K, Halfvarson J, Irving PM, Jahnsen J, Lakatos PL, Lee J, Makri S, Parker B, Peyrin-Biroulet L, Schreiber S, Simoens S, Westhovens R, Danese S, Jeong JH. The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. Drugs 2020;80:99-113. [PMID: 32002851 DOI: 10.1007/s40265-020-01256-5] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 13.3] [Reference Citation Analysis]
16 Murdoch B, Caulfield T. The Law and Ethics of Switching from Biologic to Biosimilar in Canada. J Can Assoc Gastroenterol 2020;3:228-33. [PMID: 32905067 DOI: 10.1093/jcag/gwz043] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
17 Sharma A, Hafeez Faridi M, Kumar N, Parachuri N, Sharma R, Kuppermann BD, Bandello F, Loewenstein A, Regillo CD. Immunogenicity and efficacy after switching from original Ranibizumab to a Ranibizumab biosimilar: real-world data. Eye (Lond) 2020;34:1008-9. [PMID: 31844168 DOI: 10.1038/s41433-019-0745-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
18 Moayyedi P, Benchimol EI, Armstrong D, Yuan C, Fernandes A, Leontiadis GI. Joint Canadian Association of Gastroenterology and Crohn's Colitis Canada Position Statement on Biosimilars for the Treatment of Inflammatory Bowel Disease. J Can Assoc Gastroenterol 2020;3:e1-9. [PMID: 32010877 DOI: 10.1093/jcag/gwz035] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
19 Na S. Asian Physician's Perspectives on Biosimilars in Inflammatory Bowel Disease: Are We Ready to Use? Korean J Gastroenterol 2019;74:301. [DOI: 10.4166/kjg.2019.74.6.301] [Reference Citation Analysis]